Amgen bets on ChemoCentryx’s rare disease drug in $3.7 billion deal Reuters Aug 5, 2022 Amgen has been facing stiff competition for its top-selling arthritis drug, Enbrel, from newer branded treatments and patents for…
M&As in bio/pharma industry high despite COVID-19: GlobalData EP News Bureau Dec 25, 2020 Down only 13 per cent compared with last year, with a total deal value of $228 billion compared with $262 billion in 2020, and…
